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Background: The lazaroid U74500A is a 21-aminosteroid that inhibits lipid 
peroxidation and attenuates ischemia-reperfusion i jury. We examined the 
effect of U74500A on heart preservation with the use of a clinically relevant 
canine orthotopic heart transplantation model. Methods and results: Six 
donor dogs (group L) were pretreated intravenously with U74500A (10 
mg/kg), and the dogs without pretreatment served as a control (group C, 
u = 6). The donor heart was preserved in cold University of Wisconsin 
solution for 24 hours. The heart was then transplanted orthotopically. 
Myocardial biopsy was performed to measure the adenosine triphosphate 
level at the end of ischemia. Before reperfusion, recipients in group L 
received another dose of U74500A (10 mg/kg) intravenously. After 3 hours 
of reperfusion, left ventricular function was evaluated by left ventricular 
pressure-volume relations with the use of a Millar catheter and conduc- 
tance catheter, thereby deriving the slope of the end-systolic pressure- 
volume relation, the slope of the stroke work-end-diastolic volume relation, 
and the slope of the maximum dP/dt-end-diastolic volume relation. At the 
same time, serum creatine kinase MB isoenzyme and lipid peroxide levels 
were measured. The slopes of the end-systolic pressure-volume relation, the 
stroke work-end-diastolic volume relation, and the maximum dP/dt-end- 
diastolic volume relation for group L were significantly higher than those 
for group C. The adenosine triphosphate l vels for group L were signifi- 
cantly higher than those for group C. Serum creatine kinase MB isoenzyme 
and lipid peroxide levels for group L were significantly lower than those for 
group C. Conclusions: Inhibition of lipid peroxidation by the administration 
of U74500A was effective for 24-hour canine cardiac preservation. These 
results indicate that U74500A is a promising agent for heart allograft 
preservation. (J Thorac Cardiovasc Surg 1996;112:1017-26) 
C ardiac transplantation is lifesaving for more than 3000 patients with end-stage heart diseases every 
year. 1 Unfortunately, its application is limited by the 
scarcity of donors. Adequate preservation of the 
cardiac allograft during the ischemic period is of 
paramount importance because of the increasingly 
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longer travel times for donor organs and the limited 
supply of donors. 
Despite improvements in graft preservation, sur- 
gical technique, and transplantation immunology, 
the clinically acceptable ischemic time for heart 
grafts remains 6 hours, and the prolonged ischemic 
time is one of the risk factors for 1-year heart 
transplantation mortality] Ischemia-reperfusion n- 
jury is the cause of the cardiac dysfunction of 
transplanted hearts. 2-4 The accumulation of oxygen- 
derived free radicals and lipid peroxidation induced 
by oxygen-derived free radicals are associated with 
the occurrence of ischemia-reperfusion injury. A 
number of oxygen-derNed radical scavengers and 
lipid peroxidation i hibitors have been developed to 
reduce ischemia-reperfusion njury after heart trans- 
plantation. 5-1° 
A novel series of 21-aminosteroids called laz- 
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aroids prevent lipid peroxidation without obvious 
glucocorticoid or mineralocorticoid side effects. TM 12 
They have been effective therapeutic agents for 
acute central nervous ystem ischemia. 13' 14 We15-17 
previously reported that the inhibition of lipid per- 
oxidation by U74500A, one of the lazaroid family, is 
beneficial for attenuating ischemia-reperfusion in- 
jury of heart and lung in a variety of models. For this 
agent o be applied for human heart transplantation, 
experiments that use large animals are necessary. 
This study describes the in vivo efficacy of the 
prevention of lipid peroxidation with U74500A in 
the canine orthotopic heart transplantation model. 
Materials and methods 
Donor preparation. Twelve adult mongrel dogs were 
divided randomly into two groups: the lazaroid-adminis- 
tered group (group L) and the control group (group C). 
All donor dogs were anesthetized with sodium pentobar- 
bital (30 mg/kg intravenously), followed by atropine sul- 
fate (0.04 mg/kg intramuscularly). They were then intu- 
bated with an 8.5F endotracheal tube. Mechanical 
ventilation was instituted with a tidal volume of 25 ml/kg 
at a rate of 12 breaths/min, with a positive end-expiratory 
pressure of 5 cm H20, and with an inspired oxygen 
fraction of 1.0. The dogs were placed in a supine position. 
Pancuronium bromide was administered intravenously for 
muscle relaxation. A continuous infusion of sodium pen- 
tobarbital was used to maintain anesthesia. An antibiotic, 
flomoxef (25 mg/kg intravenously), was administered to 
prevent infection. Systemic blood pressure was continu- 
ously monitored by a right femoral arterial catheter. 
After a median sternotomy, the ascending aorta, the 
main pulmonary artery, both venae cavae, and the aortic 
arch were isolated, and the azygos vein was ligated. A 
catheter-tip micromanometer (model MPC-500, Millar 
Instruments, Inc., Houston, Tex.) was inserted into the 
left atrial appendage for the left atrial pressure measure- 
ment, and a 14F ultrasonic flow probe (Transonic Sys- 
tems, Inc., New York, N.Y.) was positioned around the 
ascending aorta for the measurement of aortic flow. 
Aortic flow was measured at the left atrial pressure of 7 
mm Hg for the assessment of cardiac function of the 
pretransplantation donor heart. Heparin sodium (500 
U/kg intravenously) was administered systemically, and a 
modified 14F double-lumen cannula (Retroplegia Coro- 
nary Sinus Cardioplegic Cannula, Research Medical, Inc., 
Midvale, Utah) was inserted through the brachiocephalic 
artery to the aortic root. After an intravenous infusion of 
Ringer's lactate solution, 800 to 1000 ml of blood was 
removed from the cannula. The blood was later used to 
prime the heart-lung machine for the recipient operation. 
During blood removal, the aortic root pressure was con- 
tinuously monitored to maintain the pressure above 80 
mm Hg. 
Six donor dogs in group L were pretreated with 
U74500A (10 mg/kg intravenously) 15 minutes before the 
heart was arrested, and six donor dogs in group C without 
pretreatment served as the control subjects. U74500A was 
solved in a CS-4 solution (citric acid monohydrate, 0.02 
mol/L; sodium citrate dihydrate, 0.0032 tool/L; NaC1, 
0.077 tool/L; The Upjohn Co., Kalamazoo, Mich.). After 
the aorta was crossclamped between the brachiocephalic 
artery and the left subclavian artery, the hearts of all 
donor dogs were arrested by the infusion of cold crystal- 
loid cardioplegic solution (K ÷, 20 mmol/L; Na +, 87 
mmol/L; Ca 2+, 0.1 mmol/L; CI-, 97 mmol/L; HCO3-  , 10 
mmol/L; glucose, 25 gm/L) used in the Kyushu University 
Hospital. TM Fifteen milliliters of solution per kilogram of 
body weight was infused over 2 minutes with a rotating 
pump (Mera blood pump HCP-100, Senko Medical In- 
strument, Tokyo, Japan). The left atrial appendage was 
amputated, and the inferior vena cava was opened to 
decompress the heart. The hearts were then flushed with 
the same amount of University of Wisconsin (UW) solu- 
tion (ViaSpan, DuPont Pharmaceuticals, Wilmington, 
Del.) over 2 minutes. The temperature of the solution was 
maintained at 4 ° C by a heat exchanger (Mera Hot & Cool 
Unit MSH-51, Senko Medical Instrument, Tokyo, Japan). 
The hearts were removed with a standard technique, 
placed in a plastic bag containing cold UW solution, and 
preserved at 1 ° C for 24 hours. 
Recipient preparation. After 24 hours, the hearts were 
transplanted to 12 weight-matched recipient dogs by a 
standard technique of orthotopic heart transplantation. 
All recipient dogs were anesthetized and pretreated in the 
same manner as the donor dogs, and the recipients 
received 500 mg of methylprednisolone i travenously and 
50 mg of indomethacin rectally after induction. Sodium 
pentobarbital was drip-infused intravenously to maintain 
anesthesia. Systemic blood pressure was continuously 
monitored by a right femoral arterial catheter. 
All recipients were placed in a supine position. After a 
median sternotomy, the pericardium was incised and 
fashioned into a cradle. The ascending aorta, the main 
pulmonary artery, and both venae cavae were isolated, 
and the azygos vein was ligated. A heartqung machine 
consisted of a centrifugal pump (Bio-pump BP-80, 
Medtronic Bio-Medicus, Eden Prairie, Minn.), and a 
membrane oxygenator (D705 Midiflo System, Dideco, 
Milandola, Italy) was primed with the blood from the 
donor dog. After the administration of heparin (500 U/kg 
intravenously), cardiopulmonary b pass with moderate 
hypothermia was instituted through thin-walled, angled 
metal venous cannulas (20F Pacifico Venous Canuula, 
DLP, Grand Rapids, Mich.) through the superior and 
inferior venae cavae and an arterial cannula (3.8 mm high 
flow aortic arch cannula, Sarns/3M Health Care, Ann 
Arbor, Mich.) through the ascending aorta. 
After crossclamping of the ascending aorta, the recipi- 
ent heart was removed, and the donor heart was trans- 
planted. The anastomosis was performed in the order of 
the left atrium, the right atrium, the main pulmonary 
artery, and the ascending aorta. A continuous over-and- 
over suture of 4-0 polypropylene suture was used for the 
left and right atrial suture, and 5-0 polypropylene suture 
was used for the main pulmonary artery and the ascending 
aorta. The left ventricle was vented with a 12F thin walled 
catheter (Kuraray Co., Okayama, Japan) through the left 
atrial appendage. The donor hearts were topically cooled 
with ice slush during the procedure. After completion of 
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the right atrial and main pulmonary arterial anastomoses, 
the hearts were flushed with a 5 ml/kg concentration of 
4 ° C crystalloid cardioplegic solution. 
Before reperfusion, recipients in group L received 
another dose of U74500A (10 mg/kg intravenously). The 
aorta was declamped, the air was removed from the aorta 
and the left ventricle, and the heart was electrically 
defibrillated, if necessary. Fifteen minutes after reperfu- 
sion, calcium chloride was received to correct serum 
calcium level, and 30 minutes after reperfusion, ventricu- 
lar pacing was instituted with a rate of 140 to 150 
beats/min. All recipients were disconnected from cardio- 
pulmonary bypass 60 minutes after reperfusion without 
inotropic or vasodilatory agents. 
A right heart bypass preparation was then established 
as follows. ~9'2° A purse-string suture was placed at the 
right ventricular outflow tract, and a 16F arterial cannula 
(William Harvey arterial perfusion cannulas, C.R. Bard, 
Inc., Tewksbury, Mass.) was inserted into the main pul- 
monary artery. The tapes around the superior and inferior 
venae cavae were snared to direct systemic venous blood 
return into a reservoir. The blood oxygenated with a 
membrane oxygenator was pumped back to the main 
pulmonary artery. Pulmonary valvular regurgitation was 
prevented by snaring the tape around the main pulmonary 
artery. Another 12F thin walled catheter was placed in the 
right ventricle through the right atrium to drain the entire 
coronary venous return for the flow measurement and the 
oximetry. Coronary flow was measured by an in-line 
electromagnetic flow probe (Nihon Kohden, Tokyo, Ja- 
pan). To measure the left ventricular (LV) volume, a 
purse-string suture was placed at the LV apex, and an 8F 
eight-electrode conductance catheter (Webster, Inc., 
Baldwin Park, Calif.) was inserted into the left ventricle 
through the apex, and the tip of the catheter was posi- 
tioned just above the aortic valve. The catheter was 
attached to a signal generator-processor (Sigma 5, Ley- 
corn, Oegstageest, The Netherlands). 21-23 A catheter-tip 
micromanometer was inserted into the left ventricle for 
the LV pressure measurement, and the LV pressure- 
volume loop was then measured. A 14F ultrasonic flow 
probe was positioned around the ascending aorta for the 
measurement of aortic flow to calibrate the volume signal 
of the conductance catheter. To control the LV venous 
return and to completely decompress the right ventricle, 
right heart bypass was instituted, thereby eliminating 
parallel conductance variation. 
The heart rate was fixed at 140 to 150 beats/rain by 
pacing during the assessment period. All signals (e.g., 
electrocardiogram, pressures, flows, volume) were contin- 
uously monitored on a multichannel oscillograph (poly- 
graph 360 system, NEC Sanei, Tokyo, Japan) and on-line 
digitized at 200 Hz with an analog-to-digital converter 
(MacLab System, ADInstruments, Ltd., Dunedin North, 
New Zealand) and recorded on a digital computer 
(Macintosh Quadra 700, Apple Computer, Inc., Cuper- 
tino, Calif.). 
After the study, all dogs were killed by means of an 
overdose of intravenous sodium pentobarbital nd potas- 
sium chloride. The heart was removed from the chest, and 
the right ventricle and the left ventricle (free wall plus 
septum) were weighed. LV free wall specimens were 
taken for the myocardial water content measurement. 
Data analysis 
Conventional hemodynamic variables. At 90, 120, 150, 
and 180 minutes after reperfusion, conventional hemody- 
namie variables (i.e., heart rate, left atrial pressure, mean 
aortic pressure, and aortic flow) were obtained. The left 
atrial pressure was maintained around 10 mm Hg during 
the assessment period. 
Volume signal calibration. Conductance catheter vol- 
umes were calibrated by cardiac output (the amount of 
aortic flow and coronary flow). 23 The parallel conductance 
volume was calculated by transiently altering blood con- 
ductivity by the injection of hypertonic saline solution (5 
ml of 10% NaC1). 21' 22 
Ventricularfunction. At 90, 120, 150, and 180 minutes 
after reperfusion, multiple LV pressure-volume loops 
were obtained during transient preload reduction by 
reducing right heart bypass flow for the assessment of LV 
contractility and stiffness. The digitized data were ana- 
lyzed by computer algorithms with a C-language-type 
program developed in our laboratory with an Intel 486 
personal computer (Vision, IBM Japan, Tokyo, Japan). 
LV contractility was assessed by the end-systolic pressure- 
volume (Pes-Ves) relation, ~ the stroke work-end-dia- 
stolic volume (SW-Ved) relationy and the maximum 
dP/dt-Ved (dP/dtm~-Ved) relationY" 27 The Pes-Ves re- 
lation was fit by linear regression tO obtain a slope (Ees) 
and volume intercept (Vo,es) as follows: 
Pes = Ees (Ves - V0,es) 
To quantify the position of the Pes-Ves relation in the 
operating range, the volume (Vloo,es) associated with a 
Pes of 100 mm Hg was calculated as follows: 
V100,es = V0,es + 100/Ees 
SW was calculated as the area of each pressure-volume 
loop and was plotted against Ved as follows: 
SW = Msw (Ved - V0,sw) 
Msw is the slope of the SW-Ved relation and Vo_sw is 
the volume intercept of the SW-Ved relation. End-dia- 
stolic point was defined as the point of the rapid upstroke 
of the first derivative of the LV pressure (dP/dt). The 
position of the SW-Ved relation in the operating range 
was calculated by determining Ved associated with SW of 
500 mm Hg. ml: 
Vs~0,sw = V0,sw + 500/Msw 
dP/dt ..... and Ved were fit to 
dP/dt .... = dE/dtma~ (Ved-V0.dP/at) 
In these equations, dE/dtma x is the slope of the dP/ 
dt .... -Ved relation, and V0,dP/d t is the volume intercept of 
the dP/dtm~-Ved relation. The position of the dP/dtma x- 
Ved relation in the operating range was calculated by 
determining Ved associated with dP/dtma ×of 1000 mmHg/ 
see :  
V[000,dP/dt = V0,dP/d t @ 1000/dE/dt . . . .  
1020 Tanoue et aL 
The Journal of Thoracic and 
Cardiovascular Surgery 
October 1996 
120 
~80 - 
-g 
~- 40 
>, 
0 
0 1 () 210 
LV Volume (ml) 
Fig. 1. Representative LV pressure-volume relations de- 
rived from a transient preload reduction at 180 minutes 
after reperfusion in groups L and C. 
Table I. Data on donor and recipient operations 
Group L Group C p 
(n = 6) (n = 6) Value 
Donor weight (kg) 15.1 ± 2.0 15.8 -+ 2.6 NS 
Recipient weight (kg) 14.8 ± 1.9 15.4 ± 2.3 NS 
Aortic flow (ml/min) 1229 +_ 587 1412 _+ 676 NS 
Total ischemic time (h) 24.5 _+ 1.0 24.4 ± 1.6 NS 
Implantation time (min) 68.2 ± 6.2 69.3 ± 9.4 NS 
Aortic crossclamp time (min) 74.5 ± 6.1 76.8 ± 9.6 NS 
CPB time (min) 139.8 ± 10.5 141.3 ± 10.3 NS 
Aortic flow was measured ata left atrial pressure of 7 mm Hg. CPB, 
cardiopulmonary bypass; NS, not significant. Data are presented asmean 
± standard deviation. 
LV stiffness (the inverse of compliance) was deter- 
mined by fitting end-diastolic pressure volume points to 
the exponential relation: 
Ped= a(e ~vea) 
in which Ped and Ved are the end-diastolic pressure and 
volume points, respectively; c~ is the Ped intercept at V = 
0 ml; and/3 is a unit less modulus of chamber stiffness used 
to describe the degree of curvature of the Ped-Ved 
relation. 2s 
Myocardial energetics. During 150 to 180 minutes after 
reperfusion, multiple steady-state pressure-volume loops, 
coronary flow, and arteriovenous oxygen difference data 
were obtained at various preload volumes for the assess- 
ment of myocardial energetics. Preload was reduced in 
gradual steps by slowing the speed of pump flow. With 
each load change, all variables were allowed to equilibrate 
for 5 minutes before recording. Myocardial energetics 
were assessed by analysis of the relation between the LV 
myocardial oxygen consumption (MVO2) and the LV 
systolic pressure-volume area (PVA). The MVO2-PVA 
relation was described by Suga. 24' 29 MVO2 was calculated 
from the product of coronary flow in milliliters per 
minutes and coronary arteriovenous oxygen difference in 
volumes percent. This quantity was divided by the heart 
Table II. Comparisons of the hemodynamics of
groups L and C at 90, 120, 150, and 180 minutes 
after reperfusion 
Time after LAP Mean AoP AoF 
reperfusion HR (mm Hg) (ram Hg) (ml/min) 
90 min 
Group L 142 +_ 7 9.8 _+ 1.1 96.3 ± 12.9 583 ± 258 
Group C 148 ± 10 10.5 _+ 0.3 85.1 +_ 20.3 407 ± 184 
p value NS NS NS NS 
120 rain 
Group L 141 + 8 10.3 _+ 0.5 93.7 +_ 14.2 669 + 167 
Group C 150 ± 11 10.8 ± 0.6 87.1 -+ 10.1 466 ± 143 
p value NS NS NS NS 
150 min 
Group L 143 ± 6 9.7 _+ 1.2 95.0 ± 11.4 656 -+ 86 
Group C 145 _+ 12 10.7 ± 0.8 68.4 ± 13.9 331 ± 135 
p value NS NS 0.0046 0.0006 
180 min 
Group L 143 ± 6 9.9 _+ 0.6 94.9 ± 12.0 654 +_ 153 
Group C 145 ± 9 10.5 _+ 0.2 69.9 ± 15.4 325 ± 163 
p value NS NS 0.0106 0.0048 
HR, Heart rate; LAP, left atrial pressure; mAOP, mean aortic pressure; 
AOF, aortic flow; NS, not significant. Data are presented asthe mean -+ 
standard eviation. 
rate to yield oxygen consumption per beat, MVO2, in 
milliliters of oxygen per beat. It was normalized with 
respect o the LV weight to give MVO2 in milliliters of 
oxygen per beat per 100 gm of the left ventricle. The 
oxyhemoglobin percent saturations of the coronary arte- 
rial and venous blood were measured with a pH and blood 
gas analyzer (model 238, Ciba Coming, Medfield, Mass.), 
which was calibrated with a galvanometric oxygen content 
analyzer (Cavitron/Lex 02 Con-K, Cavitron Cardiopul- 
monary, Anaheim, Calif.). 
PVA is the area in the pressure-volume diagram cir- 
cumscribed by the Pes-Ves relation and Ped-Ved relation 
curves and the systolic segment of pressure-volume tra- 
jectory. The unit of PVA is millimeters of mercury times 
milliliters. PVA was normalized with respect o the LV 
weight and expressed in millimeters of mercury times 
milliliters per beat per 100 gm of the left ventricle. PVA 
was obtained in steady state contractions with fixed pre- 
load. 
Coronary vascular esistance. At 60, 90, 120, 150, and 
180 minutes after reperfusion, coronary vascular resis- 
tance (CVR) was calculated as follows: 
CVR = (ARP/CF) × 80 (dyn • sec/cm 5) 
where ARP is the aortic root pressure measured by 
another catheter-tip micromanometer inserted into the 
ascending aorta and CF is coronary flow. 
Myocardial adenosine triphosphate assessment. Myocar- 
dial biopsy was performed to measure the myocardial 
adenosine triphosphate (ATP) level at the end of isch- 
emia. Biopsy was performed with an 18-gauge biopsy 
needle (Bard Biopty, C.R. Bard, Inc., Convington, Ga.) at 
the LV free wall before reperfusion. Samples were rapidly 
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Table IIl. Comparisons of the Pes-Ves, SW-Ved, and dP/dtmo_~-Ved relations for groups L and C at 90, 120, 
150, and 180 minutes after reperfusion 
Pes-Ves relation 
Time after 
reperfusion Ees (ram Hg/ml) Vo,es (ml) Vloo,es (ml) 
90 rain 
Group L 10.0 _+ 2.7 4.3 _+ 6.5 14.9 ± 7.7 0.985 ± 0.010 
Group C 7.9 -+ 4.4 18.8 ± 12.5 37.7 ± 24.5 0.986 ± 0.013 
p Value NS 0,0299 NS 
120 rain 
Group L 10.4 ± 2.7 3.3 ± 5,7 13.6 ± 7.0 0.986 ± 0.011 
Group C 7.2 ± 2.8 15.5 ± 14.5 31.4 ± 19.5 0.975 ± 0.022 
p Value NS NS NS 
15 rain 
Group L 9.9 ± 3.6 1.7 ± 4.6 13.0 ± 6.2 0.981 + 0.022 
Group C 5.6 ± 2.8 14.1 ± 11.9 35.4 _+ 16.7 0.965 ± 0.042 
p Value 0.0431 0.0377 0.0113 
180 min 
Group L 9.9 ± 2.9 1.1 ± 4.0 12.0 ± 4.2 0.976 ± 0.024 
Group C 5.8 + 2.9 14.3 ± 13.1 35.0 + 19.2 0.957 ± 0.040 
p Value 0.0345 0.0390 0.0169 
SW-Ved relation 
Time after 
repetfusion Msw (ram Hg) Vo,sw (ml) Vsoo,SW (ml) 
90 rain 
Group L 54.6 ± 15.6 10.3 ± 6.5 20.2 ± 6.7 0.976 ± 0.015 
Group C 52.2 ± 22.2 32.4 ± 20.5 43.5 ± 22.7 0.957 ± 0.060 
p Value NS 0.0306 0.0361 
120 rain 
Group L 60.7 ± 14.2 9.9 -+ 6.4 18.5 ± 5.4 0.983 ± 0.009 
Group C 47.0 + 23.9 26.3 ± 17.8 39.1 ± 19.2 0.962 ± 0.020 
p Value NS NS 0.0295 
150 rain 
Group L 60.6 ± 11.4 9.0 ± 4.5 17.6 ± 5.1 0.985 _+ 0.009 
Group C 38.1 ± 10.7 28.9 ± 18.5 42.9 ± 17.1 0.920 _+ 0.056 
p Value 0.0055 0.0287 0.0060 
180 min 
Group L 61.3 ± 17.6 8.3 ± 3.6 17.1 _+ 2.4 0.982 ± 0.011 
Group C 42.7 ± 9.1 28.9 ± 19.5 41.0 ± 19.6 0.928 ± 0.080 
p Value 0.0438 0.0297 0.0141 
dP/dt,~- Ved relation 
Time after dE/dtm~ 
reperfusion (mm Hg/(sec .ml)) Vo, ap/d , (ml) Vzooo, de/dr (ml) 
90 rain 
Group L 79.7 ± 25.8 2.7 _+ 5.8 15.9 + 7.8 0.923 _+ 0.140 
Group C 66.6 ± 33.8 18.7 ± 18.2 40.5 + 26.1 0.975 ± 0.016 
p Value NS NS NS 
120 rain 
Group L 82.9 ± 28.7 2.1 _+ 5.8 14.9 ± 7.9 0.924 _+ 0.141 
Group C 60.8 ± 22.6 15.6 ± 18.8 35.0 ± 23.4 0.969 ± 0.018 
p Value NS NS NS 
150 min 
Group L 75.7 ± 30.9 -0.2 ± 5.6 14.4 _+ 7.6 0.927 ± 0.142 
Group C 44.4 ± 13.1 12.0 ± 16.8 36.2 _+ 16.7 0.948 _+ 0.032 
p Value 0.0460 NS 0.0154 
180 rain 
Group L 82.7 ± 30.4 -1.5 ± 2.4 12.3 _+ 4.9 0.977 ± 0.014 
Group C 41.3 -+ 12.7 9.3 + 17.2 35.9 + 20.8 0.951 _+ 0.036 
p Value 0.0116 NS 0.0221 
LV, left ventricular; Pes, LV end-systolic pressure; Ves, end-systolic volume; Ees, slope of Pes-Ves relation; V o,es, volume axis intercept of Pes-Ves relation; 
Vlo o ,es, Ves associated with Pes of 100 mm Hg; ~; mean value of correlation coefficient; NS, not significant; SW; LV stroke work; Ved, end-diastolic volume; 
Msw, slope of SW-Ved relation; Vo.sw,, volume intercept of SW-Ved relation; Vsoo.sw. Ved associated with SW of 500 ml - mm Hg; dP/dt~a~ maximum rate 
of change of LV pressure; dE/dt ..... slope of dP/dtm~,-Ved relation; Vo~e/et, volume intercept of dP/dtm,x-Ved relation Vlooo.ap/,l v Ved associated with 
dP/dtma× of 1,000 mm Hg/sec. Data are presented as mean _+ standard eviation. 
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Table IV. Comparisons of the Ped-Ved relation 
between groups L and C at 90, 120, 150, and 180 
minutes after reperfusion 
Time after 
reperfusion [3 ~ r 
90 rain 
Group L 0.098 _+ 0.020 1.72 ± 0.81 0.986 ± 0.013 
Group C 0.107 +_ 0.029 1.26 ± 0.43 0.992 +_ 0.005 
p Value NS NS 
120 min 
Group L 0.103 + 0.020 1.65 +- 0.91 0.985 ± 0.013 
Group C 0.103 ± 0.023 1.30 ± 0.39 0.988 _+ 0.012 
p Value NS NS 
150 min 
Group L 0.109 ± 0.022 1.65 +- 0.91 0.987 ± 0.014 
Group C 0.094 _+ 0.032 1.28 _+ 0.48 0.973 ± 0.037 
p value NS NS 
180 rain 
Group L 0.109 ± 0.038 1.27 ± 0.59 0.990 _+ 0.006 
Group C 0.096 _+ 0.034 1.34 ± 0.50 0.960 _+ 0.060 
p Value NS NS 
Ped, LV end-diastolic pressure; Ved, end-diastolic volume; /3, degree of 
curvature of Ped-Ved relation; c~, volume intercept of Ped-Ved relation; r, 
mean value of correlation coefficient; NS, not significant. Data are 
presented as mean -+ standard eviation. 
frozen with liquid nitrogen and preserved in liquid nitro- 
gen until analysis. ATP was measured with the use of 
high-pressure liquid chromatography as previously de- 
scribed) ° 
Serum chemistry. Serum creatine kinase MB (CK-MB) 
isoenzyme and lipid peroxide levels were measured 180 
minutes after reperfusion. Serum lipid peroxide levels 
were measured by a methylene blue derivative method) 1 
Myocardial water content. LV free wall specimens taken 
after experiments were weighed just after collection (wet 
weight) and after 24 hours' desiccation (dry weight). The 
myocardial water content was calculated by the following 
formula: 
Myocardial water content = 
(wet weight - dry weight)/wet weight × 100 (%) 
Statistical analysis. Results are presented as the 
mean + one standard eviation. The Student's t test was 
used to analyze the differences. Ap value less than 0.05 
was considered significant. 
Animal care. All animals have received humane care in 
compliance with the "Principles of Laboratory Animal 
Care" formulated by the National Society for Medical 
Research and the "Guide for the Care and Use of 
Laboratory Animals" prepared by the Institute of Labo- 
ratory Animal Resources and published by the National 
Institutes of Health (NIH Publication No. 86-23, revised 
1985). This experiment was reviewed by the Committee of 
the Ethics on Animal Experiment in Faculty of Medicine, 
Kyushu University, and carried out under the control of 
the Guidelines for Animal Experiment in Faculty of 
Medicine, Kyushu University, and The Law (No. 105) and 
Notification (No. 6) of the Government. 
Table V. Comparisons of the MVO2-PVA relation 
for groups L and C 
Slope (×I0 -s) Intercept (?<10 -2) r 
Group L 1.02 _+ 0.60 1.30 + 0.88 0.950 + 0.098 
Group C 0.94 + 0.78 1.17 + 0.32 0.933 +- 0.095 
p Value NS NS 
MVO2, Myocardial oxygen consumption; PVA, systolic pressure-volume 
area; 1; mean value of correlation coefficient; NS, not significant. Data are 
presented as mean _+ standard eviation. 
Results 
All the dogs in both groups were successfully 
disconnected from cardiopulmonary b pass. No sig- 
nificant difference was observed between the two 
groups in regard to donor weight, recipient weight, 
and aortic flow measured at the left atrial pressure 
of 7 mm Hg. Mean ischemic preservation times 
(total ischemic time and implantation time) were 
similar for the two groups. Aortic crossclamp and 
cardiopulmonary b pass times were also similar for 
the two groups (Table I). 
Conventional hemodynamic variables. Conven- 
tional hemodynamic variables at 90, 120, 150, and 
180 minutes after reperfusion are provided in Table 
II. Mean aortic pressure and aortic flow in group L 
were higher than those in group C at 150 and 180 
minutes after reperfusion. 
Ventricular function. Representative multiple 
LV pressure-volume loops of two groups are shown 
in Fig. 1. Parameters of systolic ventricular function 
at 90, 120, 150, and 180 minutes after reperfusion 
are provided in Table III. Although the differences 
of Ees between the two groups were not significant 
at 90 and 120 minutes after reperfusion, Ees in 
group C decreased gradually, and the differences 
reached statistical significance at 150 and 180 min- 
utes after reperfusion. Similar significant differences 
were observed in Msw and dE/dtma x between groups 
L and C at 150 and 180 minutes after reperfusion. 
The differences of V0,es and V0,sw between the two 
groups were significant at 90, 150, and 180 minutes 
after reperfusion. All three relations for group L 
were shifted toward the left in the operating range 
compared with group C, manifested by V10o,es, 
Vso0,sw, and Vl000,dP/dt. Although there were no 
significant differences between the two groups up to 
120 minutes after reperfusion, Vl00,es and Vl000,dP/dt 
for group L was significantly lower than the values 
for group C at 150 and 180 minutes after reperfu- 
sion. At each time point, there were significant 
differences in Vs00,sw between the two groups. 
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Fig. 2. The changes of CVR at 90, 120, 150, and 180 minutes after reperfusion i groups L and C. Data 
are presented as the mean _+ 1 standard eviation. NS, Not significant. 
Diastolic ventricular function parameters at 90, 
120, 150, and 180 minutes after reperfusion are 
provided in Table IV. There were no significant 
differences in the degree of curvature that reflected 
end-diastolic chamber stiffness, 13, and the volume 
intercept of Ped-Ved relation, ~, between groups L 
and C. 
Myocardial energetics. Differences inthe MVO 2- 
PVA relation between groups L and C are shown in 
Table V. The slope and intercept of the MVO2-PVA 
relation were similar for the two groups. 
CVR. The changes of CVR at 90, 120, 150, and 
180 minutes after reperfusion are shown in Fig. 2. 
CVR in group L was lower than that in group C 
throughout the assessment period, but the differ- 
ence between the two groups did not reach statisti- 
cal significance. 
Myocardial ATP. ATP level at the end of isch- 
emia in group L was significantly higher than that in 
group C: 28.09 _+ 15.17/xmol/gm and 12.59 ± 2.68 
/xmol/gm (p = 0.0334), respectively (Fig. 3). 
Serum chemistry. Serum CK-MB and lipid per- 
oxide levels at 180 minutes after reperfusion in 
group L were significantly ower than those in group 
C (Fig. 4). The values of serum CK-MB level in 
groups L and C were 88.0 +_ 72.8 ng/ml and 292.2 + 
162.5 ng/ml (p = 0.0185), respectively. The values of 
serum lipid peroxide level in groups L and C were 
0.05 ± 0.39 nmol/ml and 1.74 _+ 1.77 nmol/ml (p = 
0.0455), respectively. 
Myocardial water content. There was no signifi- 
cant difference in the myocardial water content 
between groups L and C: 78.9% _+ 2.5% and 78.9% 
± 1.2% (p = 0.9473), respectively. 
Discussion 
Lipid peroxidation involving polyunsaturated 
fatty acids in cell membranes i a free radical- 
induced chain reaction initiated by the hydroxyl 
radical formed during the ischemia-reperfusion pe- 
riod. Lipid peroxidation severely damages the cell 
membrane, produces loss of fluidity, and triggers the 
breakdown of membrane secretory functions and 
transmembrane ionic gradients. 32
Lazaroids are 21-aminosteroids that prevent lipid 
peroxidation without obvious glucocorticoid ormin- 
eralocorticoid side effectsJ 1' 12 U74500A, one agent 
of the lazaroid family, is a potent inhibitor of 
iron-catalyzed lipid peroxidation. 12 U74500A has 
been effective in a variety of models of ischemia- 
reperfusion in jury .  15-17'33-38 Killinger and col- 
leagues, 38 who used an umbilical vein endothelial 
cell culture model, studied the effects of lazaroids as 
additives to preservation solutions. They reported 
that the addition of lazaroids to organ preservation 
solutions greatly improved endothelial cell viability. 
We 15 previously reported that the inhibition of lipid 
peroxidation by the pretreatment with U74500A 
prevented myocardial contracture and preserved LV 
function after 35 minutes of normothermic global 
ischemia in an isolated blood-perfused rabbit heart 
preparationJ 5 We also reported the beneficial ef- 
fects of the prevention of lipid peroxidation with 
U74500A for 24-hour heart preservation i an iso- 
lated blood-perfused rabbit working heart modelJ 6 
Because experimentation with a large animal 
model was mandatory for the clinical application of 
this agent, we used a canine orthotopic heart rans- 
plantation model. In the current study, we demon- 
strated the beneficial effect of the inhibition of lipid 
peroxidation by administering U74500A for canine 
heart grafts preserved for 24 hours. Throughout the 
180-minute assessment period after reperfusion, the 
dogs treated with U74500A showed better systolic 
ventricular function than did dogs without the 
U74500A treatment. The serum CK-MB and lipid 
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Fig. 3. ATP level at the end of ischemia in groups L and 
C: Data are presented as the mean _+ 1 standard evia- 
tion. 
peroxide levels in the dogs treated with U74500A 
were lower than those of dogs without he U74500A 
treatment. Myocardial ATP levels at the end of 
ischemia in donor hearts treated with U74500A 
remained higher than those in donor hearts without 
the U74500A treatment. 
U74500A was administered intravenously to do- 
nor dogs before preservation and to recipient dogs 
before reperfusion, because the lazaroid U74500A 
is not inherently soluble in UW solution. U74500A 
is not soluble at neutral or alkaline pH, which is the 
case for UW solution. Systemically administered 
U74500A was equally effective to that administered 
as an additive tO the preservation solution. The 
dosage of 10 mg/kg was chosen because our prelim- 
inary experiment with a 5 mg/kg concentration of 
U74500A showed no substantial benefit in cardiac 
function. Further study is warranted to show the 
dose-response effect of U74500A on preservation if 
the agent is to be applied clinically. 
We selected UW solution for the preservation 
solution because of reports that documented the 
superiority of UW solution for heart preserva- 
tion. 39-4j We have reported that storing the heart in 
intracellular-type solution provided best results, but 
to prevent coronary vasoconstriction during the 
infusion of intracellular-type solution, extracelluiar- 
type solution (crystalloid cardioplegia) should be 
used to arrest the heart. 42 We have observed that 
arresting the heart with UW solution caused re- 
markable coronary vasoconstriction (unpublished 
data). In this study, we arrested the heart by an 
extracellular-type crystalloid cardioplegic solution 
to prevent UW solution-induced vasoconstriction. 
The temperature for preservation was set to 1 ° C 
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Fig. 4. CK-MB (A) and lipid peroxide (LPO) levels (B) 
were measured 180 minutes after reperfusion i groups L 
and C. Data are presented as the mean _+ 1 standard 
deviation. 
because of studies reporting that the optimal tem- 
perature for UW solution was below 10 ° C. 43 The 
temperature was easily maintained by immersing the 
plastic bag containing the graft into ice slush. The 
cardiac preservation period of 24 hours was selected 
because our preliminary reports showed no differ- 
ence between the two groups after 6 or 12 hours of 
preservation i UW solution. 
Conventional hemodynamic variables (e.g., mean 
aortic pressure, aortic flow) of dogs treated with 
U74500A were superior to those of dogs without he 
U74500A treatment. The indices of systolic ventric- 
ular function, Ees, Msw, and dE/dtma x of dogs 
treated with U74500A were superior to those of 
dogs without the U74500A treatment. Although 
there was no difference in LV end-diastolic chamber 
stiffness between the two groups, LV pressure- 
volume loops of dogs treated with U74500A were 
shifted significantly toward the left compared with 
those of dogs without the U74500A treatment. The 
inhibition of lipid peroxidation by the administra- 
tion of the lazaroid U74500A preserved ventricular 
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function after 24 hours of ischemia in this canine 
orthotopic heart transplantation model. 
Although the difference was not significant, CVR 
after reperfusion of dogs treated with U74500A 
tended to be lower in this study. Mankad and 
colleagues 44reported that UW solution caused en- 
dothelial dysfunction i the isolated rat heart prep- 
aration. Pearl and colleagues 45showed the loss of 
endothelium-dependent vasodilatation and nitric 
oxide release after myocardial protection with UW 
solution. The fact that the pretreatment of U74500A 
tended to keep CVR at a lower level might indicate 
the effect of preservation of coronary endothelial 
function. 
The ATP level of dogs administered U74500A 
was maintained at a high level at the end of the 
24-hour ischemia period in this study. We !5 previ- 
ously reported that pretreatment with U74500A 
prevented myocardial contracture during ischemia 
in an isolated rabbit heart preparation. These results 
suggest hat U74500A has some cardioprotective 
effecl during ischemia. Although lower serum 
CK-MB and lipid peroxide levels after reperfusion 
in U74500A-treated dogs indicated the inhibition of 
lipid peroxidation, the high ATP level at the end of 
ischemia nd the prevention of myocardial contrac- 
ture during ischemla cannot be fully explained by 
the inhibition of lipid peroxidation. Some other 
mechanisms ofU74500A were indicated from these 
results. 
The limitation of our experimental model was 
that the assessment period was restricted to 180 
minutes after reperfusion, because right heart by- 
pass with a membrane oxygenator was used. To 
examine the long-term effect of U74500A, we mea- 
sured conventional hemodynamic parameters with- 
out a right heart bypass. In this preliminary study, 
the heart treated with U74500A was able to main- 
tain adequate aortic flow for up to 6 hours after 
reperfusion. 
In this study, the technique of heart transplanta- 
tion was designed as much as possible to retain 
clinical relevance Adding U74500A to the current 
heart-harvesting protocol may extend the limit of 
the safe preservation period. A 24-hour heart pres- 
ervation would be possible by combining the avail- 
able techniques and the prevention of lipid peroxi- 
dation with the lazaroid U74500A. 
The inhibition of lipid peroxidation by adminis- 
tering the lazaroid U74500A prevented lipid peroxi- 
dation and preserved systolic ventricular function 
after 24 hours of ischemia in an orthotopic anine 
heart transplantation model. These results indicate 
that U74500A is a promising agent for cardiac 
allograft preservation. 
U74500A and CS-4 solutions were provided by The 
Upjohn Company (Kalamazoo, Mich.). 
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